Most Nigerian men diagnosed with prostate cancer only find out once the disease has already spread beyond the prostate gland. In one clinic-based study, close to three in four patients presented with locally advanced or metastatic disease, at a mean age of 68, according to a review published in the Nigerian Journal of Clinical Practice. That single statistic captures the two problems this article explains: prostate cancer in African men tends to behave more aggressively, and it tends to be caught far too late.
Across sub-Saharan Africa, prostate cancer is now the most common cancer diagnosed in men, and death rates keep climbing even as they fall in wealthier countries, according to continental cancer projections published in the Journal of Global Medicine. The World Health Organization’s regional office for Africa attributes this partly to biology, since men of African descent more often carry genetic traits linked to aggressive, harder-to-treat tumours. But biology is only half the story: weak screening systems, too few specialists, and a culture of silence around men’s health complete the picture.
How common is prostate cancer in African men?
Prostate cancer is now the leading cancer among men across sub-Saharan Africa, ahead of every other malignancy in both new cases and deaths, according to a review of treatment approaches in the region. In 2022, the continent recorded an estimated 103,050 new cases and 58,890 deaths, with an incidence rate of 30.3 per 100,000 men and a mortality rate of 17.3 per 100,000, according to the Journal of Global Medicine. Southern, Middle and West Africa carry the heaviest burden.
The trend is worsening: new cases across Africa could rise by more than 170 percent by 2050, reaching over 280,000 diagnoses a year. This contrasts sharply with wealthier countries, where prostate cancer deaths have fallen for decades thanks to earlier detection and better treatment. In sub-Saharan Africa, both incidence and mortality keep climbing together.
Why the disease is more aggressive in men of African descent
African ancestry is itself an established risk factor for prostate cancer and for more aggressive disease, independent of where a man lives. Tumours in men of African descent tend to grow faster, reach a higher grade, and spread earlier than tumours in men of other backgrounds.
Genetics helps explain why. Researchers have identified gene variants that occur almost exclusively, or far more often, in men of African ancestry, including changes in the SPOP gene, a tumour-suppressor gene previously linked to aggressive disease, and in HOXB13 and ANO7, genes tied to prostate-specific risk found in genetic studies of African ancestry. Other research points to differences in immune response to early tumour cells, which may make cancer harder for the body to contain.
Most of this research, though, has been carried out on populations outside Africa. One recent genetic study found that men from sub-Saharan Africa made up only about 7 percent of the global data used to build prostate cancer risk models. Without more research based on African men themselves, doctors are working with an incomplete picture of the disease in the population it affects most.
Why prostate cancer is harder to detect early
Too few specialists and tools
Diagnosing prostate cancer properly requires a prostate-specific antigen (PSA) blood test, a digital rectal examination (DRE), and, if results are abnormal, a biopsy guided by ultrasound or magnetic resonance imaging (MRI). These tools exist unevenly across the region. A continent-wide survey of urology centres found that although PSA testing was available almost everywhere, only about half could perform a radical prostatectomy, and MRI-guided biopsy existed at only a handful of sites.
Specialists are scarce too. Nigeria has roughly one urologist for every 3.8 million people, and Ghana one for every 2.5 million, compared with one per 27,000 in the United States, according to workforce data reported in Africa Health. Radiotherapy machines are similarly concentrated in a handful of cities, forcing many patients to travel far and pay out of pocket for treatment that should be available closer to home.
Fear, embarrassment and silence
Even where testing is available, many men avoid it. Studies from Nigeria, Kenya and South Africa describe similar barriers: embarrassment about the examination, fear of pain, and a belief among men under 50 that they are too young to be at risk, despite guidelines that recommend screening conversations from age 40 for men of African ancestry. Doctors are sometimes part of the problem too, since healthcare workers often do not raise the subject unless a patient asks first.
The result is a disease that stays hidden until it announces itself through pain or urinary trouble, by which point it has often already spread. Similar delays show up across other silent conditions common in the region. For a full breakdown of how these gaps play out elsewhere, see our earlier guide on hypertension in young Africans.
Warning signs men should not ignore
Early prostate cancer often causes no symptoms at all, which is why screening matters more than waiting to feel unwell. When symptoms do appear, they can include:
- A weak or interrupted urine stream, or straining to urinate
- Passing urine more often than usual, especially at night
- Difficulty starting or stopping urination
- Blood in the urine or semen (haematuria or haematospermia)
- Pain or a burning feeling when urinating
- Erectile dysfunction
- In more advanced disease, persistent bone pain, particularly in the back, hips or pelvis, along with unexplained weight loss and fatigue
None of these symptoms confirm cancer on their own. An enlarged prostate from a common, non-cancerous condition called benign prostatic hyperplasia (BPH) can cause several of the same urinary symptoms. Only a doctor, using a blood test, examination and sometimes a biopsy, can tell the difference, so self-diagnosis is never the right approach.
When should African men start prostate cancer screening?
In the United States, the Prostate Cancer Foundation now recommends that Black men discuss a baseline PSA test with their doctor between ages 40 and 45, continuing regular checks to around 70. The guidance exists because prostate cancer tends to develop three to nine years earlier in men of African descent, and starting earlier can meaningfully lower the risk of dying from it without much added overtreatment.
Clinicians working in Nigeria echo this guidance, pointing to age 40 as when men of African ancestry should start thinking about screening, particularly if a father or brother has had prostate cancer, since a strong family history can raise personal risk several times over. Screening works best as a decision made together with a doctor, who can weigh a man’s family history, general health and personal preferences before recommending a PSA test, a DRE, or both.
Reasons for hope
Progress is visible in pockets. The HypoAfrica research consortium, launched in 2021, is testing shorter radiotherapy schedules that cut the number of hospital visits a man needs, easing the cost and travel burden that keeps patients from finishing treatment. Some countries have trained trusted local figures, including barbers, as informal health educators who encourage men to ask about screening, with encouraging early results. None of this replaces the basics of more urologists and equipment, but it shows meaningful change is possible.
Start the conversation before symptoms do
Prostate cancer in African men is not more dangerous because it cannot be caught. It is more dangerous because it is so often caught late, on top of a biology that already gives it a head start. Every man over 40, especially those with a father or brother who has had prostate cancer, should raise the subject at their next clinic visit rather than waiting for symptoms to force the conversation. That one conversation, and the test that follows it, remains the most reliable way to catch this disease while it can still be cured. This article is written to inform, not to replace a proper consultation, so any man concerned about his own risk should still see a doctor.
Frequently asked questions
At what age should African men start screening for prostate cancer? Most current guidelines suggest men of African ancestry begin discussing a baseline PSA test with their doctor from age 40, rather than waiting until 50 as average-risk men are often advised. This is because the disease tends to appear earlier and behave more aggressively in men of African descent.
What are the early warning signs of prostate cancer? Early prostate cancer usually has no symptoms at all. When they do appear, common signs include a weak urine stream, urinating more often at night, blood in the urine or semen, and erectile dysfunction. Bone pain and unexplained weight loss can signal more advanced disease.
Does a family history of prostate cancer increase my risk? Yes. Having a father or brother who has had prostate cancer can raise a man’s own risk several times over compared with men who have no family history. This is one of the strongest reasons to start screening conversations earlier rather than later.
Is the PSA test painful, and is it reliable on its own? The PSA test is a simple blood draw and is not painful. It is not perfect on its own, since other conditions such as an enlarged prostate can also raise PSA levels, which is why doctors often combine it with a physical examination and sometimes further tests before confirming a diagnosis.
Can prostate cancer be cured if it is found early? Prostate cancer found while still confined to the prostate gland responds well to treatment in most cases, whether through surgery, radiotherapy or active monitoring. Once the cancer has spread beyond the prostate, treatment shifts towards control rather than cure, which is why early detection matters so much.
About the author
Dr. Chimaobi Felix, MBBS, is the founder of The Healthy African and leads its editorial team of medical professionals. He writes to make evidence-based health information accessible to readers and practitioners across sub-Saharan Africa, drawing on current clinical guidelines and peer-reviewed research to close the gap between global medical evidence and everyday health decisions on the continent.
** This Article has been Reviewed by Dr. Chimaobi Felix, MBBS
⚕ Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health decisions. The Healthy African is not liable for any actions taken based on the information provided on this site.
